top of page

First patient treated in the Phase III ECHO-301 study

The first patient has been treated in the ECHO-301 study – a Phase III trial evaluating Incyte’s IDO1 inhibitor, epacadostat, with Merck’s Keytruda (pembrolizumab) as first-line treatment for patients with advanced or metastatic melanoma.

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page